6350.00 JPY pre-market: 4551.T Torii Pharmaceutical (JPX) 20 Feb 2026 watch 7,150.00 JPY

4551.T stock opens pre-market at 6350.00 JPY, showing an early bounce after a recent pullback on 20 Feb 2026. This move meets our oversold bounce criteria: price near short-term support, low relative volume, and a clear risk-reward entry. Torii Pharmaceutical Co., Ltd. (4551.T) trades on the JPX and reports EPS 192.43 with a PE 33.00. We use Meyka AI-powered market analysis to combine these signals for a concise trade plan and price targets.

4551.T stock pre-market action

Torii Pharmaceutical (4551.T) is trading 6350.00 JPY pre-market after opening 6340.00 JPY and a previous close at 6330.00 JPY. Volume stands at 48,100.00 versus an average 49,218.00, showing near-normal participation. The intraday range sits between 6330.00 JPY and 6350.00 JPY so far. Short-term traders should note the relative volume of 0.98, indicating limited conviction behind the bounce.

Fundamentals and valuation for 4551.T stock

Torii Pharmaceutical reports EPS 192.43 and a trailing PE 33.00, above the healthcare sector average PE 23.39. Price-to-book is 1.46, and price-to-sales is 2.81, signaling moderate premium versus peers. The company shows a current ratio 5.18 and cash per share 1203.19 JPY, indicating strong liquidity. Growth metrics show net income growth 22.41% for FY 2024, supporting the valuation despite the higher PE.

Technical snapshot: oversold bounce setup

Technicals point to a short-term oversold bounce. Keltner channel middle is 6350.00 JPY, with upper at 6390.00 JPY and lower at 6310.00 JPY, placing price at the channel center. ATR is 20.00 JPY, limiting expected one-day volatility. Day low 6330.00 JPY and day high 6350.00 JPY show a tight range. Traders can treat a close above 6390.00 JPY as confirmation of bounce continuation.

Sector context, catalysts and risks for 4551.T stock

Torii sits in Healthcare, drug manufacturers specialty and generic. The sector PE is 23.39, while Torii’s PE 33.00 implies higher growth expectations. Catalysts include new product uptake for REMITCH and CORECTIM, plus Japan Tobacco (parent) strategic support. Risks include slower adoption, receivables cycle (days sales outstanding 159.93), and limited free cash flow disclosure. Keep an eye on regulatory updates and Japan market demand.

Meyka AI rates 4551.T with a score out of 100 and forecast

Meyka AI rates 4551.T with a score out of 100: 72.71, grade B+, suggestion BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects 3-year 6581.12 JPY and 5-year 7634.08 JPY. Versus the current 6350.00 JPY, the 3-year implies +3.64% upside, and the 5-year implies +20.22%. Forecasts are model-based projections and not guarantees.

Trading strategy for an oversold bounce on 4551.T stock

For short-term traders we outline a clear plan: consider entry near 6330.00–6350.00 JPY, initial stop at 6200.00 JPY to limit downside, and a first target at 7150.00 JPY. A confirmed break above 6390.00 JPY supports a move to a secondary target 7634.08 JPY (5-year model level). Risk management should cap position size given PE premium and receivables cycle. Use limit orders and reassess after any close below the stop.

Final Thoughts

Torii Pharmaceutical (4551.T) shows a classic oversold bounce setup in the JPX pre-market session on 20 Feb 2026 with price at 6350.00 JPY. Fundamentals remain solid: EPS 192.43, strong liquidity with cash per share 1203.19 JPY, and healthy FY 2024 net income growth of 22.41%. Technical confirmation is a close above the Keltner middle 6350.00 JPY and resistance near 6390.00 JPY. Meyka AI’s forecast model projects yearly 5526.11 JPY (near-term downside), 3-year 6581.12 JPY (+3.64% vs current), and 5-year 7634.08 JPY (+20.22% vs current). Traders targeting an oversold bounce can use 6330.00–6350.00 JPY entry zones, a 6200.00 JPY stop, and a 7150.00 JPY near-term target. These figures reflect model outputs and market conditions, not guaranteed outcomes. For continuous updates see the company site and exchange pages and our Meyka AI stock page for live data.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.